Literature DB >> 22731714

Defective tight junctions in refractory celiac disease.

Michael Schumann1, Sarah Kamel, Marie-Luise Pahlitzsch, Lydia Lebenheim, Claudia May, Michael Krauss, Michael Hummel, Severin Daum, Michael Fromm, Jörg-Dieter Schulzke.   

Abstract

In celiac disease, the gut-associated immune system is activated in response to the ingestion of gluten, causing an atrophy of the small intestinal mucosa. Although this condition is, in most cases, responsive to a gluten-free diet, celiac disease refractory to treatment occurs in a small percentage of celiacs. An epithelial barrier defect is known to be an integral part of celiac pathophysiology. However, the mucosa in refractory celiac disease underlies a constant inflammatory process. The epithelial barrier has not been addressed in this condition so far. Herein, the tight junction-associated barrier in refractory celiac disease is investigated functionally and structurally. Although normally expressed in celiac disease, claudin-4 is shown to be downregulated in refractory cases, presumably by two mechanisms, reduced protein expression and increased claudin endocytosis. Furthermore, the tightening claudin-5 is downregulated and the pore-forming claudin-2 is upregulated.
© 2012 New York Academy of Sciences.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22731714     DOI: 10.1111/j.1749-6632.2012.06565.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  26 in total

1.  Claudin-2 as a mediator of leaky gut barrier during intestinal inflammation.

Authors:  J Luettig; R Rosenthal; C Barmeyer; J D Schulzke
Journal:  Tissue Barriers       Date:  2015-04-03

Review 2.  The intestinal epithelial barrier: a therapeutic target?

Authors:  Matthew A Odenwald; Jerrold R Turner
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2016-11-16       Impact factor: 46.802

Review 3.  Molecular aspects of tight junction barrier function.

Authors:  Guo Hua Liang; Christopher R Weber
Journal:  Curr Opin Pharmacol       Date:  2014-08-14       Impact factor: 5.547

4.  Enteropathogenic Escherichia coli inhibits type I interferon- and RNase L-mediated host defense to disrupt intestinal epithelial cell barrier function.

Authors:  Tiha M Long; Shahista Nisa; Michael S Donnenberg; Bret A Hassel
Journal:  Infect Immun       Date:  2014-04-14       Impact factor: 3.441

Review 5.  Human immunodeficiency virus-associated disruption of mucosal barriers and its role in HIV transmission and pathogenesis of HIV/AIDS disease.

Authors:  Sharof Tugizov
Journal:  Tissue Barriers       Date:  2016-03-03

6.  Acid-functionalized single-walled carbon nanotubes alter epithelial tight junctions and enhance paracellular permeability.

Authors:  Anand P Singh; Md Babu Mia; Rajiv K Saxena
Journal:  J Biosci       Date:  2020       Impact factor: 1.826

7.  Thrifty, Rapid Intestinal Monolayers (TRIM) Using Caco-2 Epithelial Cells for Oral Drug Delivery Experiments.

Authors:  Nicholas G Lamson; Rebecca L Ball; Katherine C Fein; Kathryn A Whitehead
Journal:  Pharm Res       Date:  2019-10-28       Impact factor: 4.200

8.  Tight Junction Ultrastructure Alterations in a Mouse Model of Enteral Nutrient Deprivation.

Authors:  Farokh R Demehri; Susanne M Krug; Yongjia Feng; In-Fah M Lee; Joerg D Schulzke; Daniel H Teitelbaum
Journal:  Dig Dis Sci       Date:  2015-12-21       Impact factor: 3.199

9.  Are alterations of tight junctions at molecular and ultrastructural level different in duodenal biopsies of patients with celiac disease and Crohn's disease?

Authors:  Pooja Goswami; Prasenjit Das; Anil K Verma; Shyam Prakash; T K Das; T C Nag; Vineet Ahuja; Siddhartha Datta Gupta; Govind K Makharia
Journal:  Virchows Arch       Date:  2014-09-21       Impact factor: 4.064

10.  Tumour necrosis factor--induced loss of intestinal barrier function requires TNFR1 and TNFR2 signalling in a mouse model of total parenteral nutrition.

Authors:  Yongjia Feng; Daniel H Teitelbaum
Journal:  J Physiol       Date:  2013-06-10       Impact factor: 5.182

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.